How should a mineralocorticoid receptor antagonist (e.g., spironolactone) be started, titrated, and monitored, and when is eplerenone preferred?

Mineralocorticoid Receptor Antagonist Therapy

Starting MRA Therapy

Start spironolactone 12.5-25 mg once daily (or eplerenone 25 mg once daily) after confirming adequate renal function (eGFR >30 mL/min/1.73 m²) and serum potassium <5.0 mEq/L. 1 For patients with severe primary aldosteronism and profound hypokalemia, consider starting at higher doses (spironolactone 50 mg/day or eplerenone 50 mg twice daily). 1

Pre-Initiation Requirements

• Check serum potassium, renal function (creatinine/eGFR), and baseline blood pressure
• Discontinue or reduce potassium supplements at day 2-4 of MRA initiation (except in severe hypokalemia cases) 1
• Counsel patients on dietary salt restriction (<5 g/day) as high-salt intake is a common cause of apparent MRA non-response 1

Titration Protocol

Increase the dose at 8-12 week intervals based on blood pressure response and potassium levels, targeting spironolactone 50-100 mg/day or eplerenone 50 mg twice daily. 1 The full drug effect may take up to 3 months in severe cases. 1

Dose Adjustment Algorithm for Primary Aldosteronism:

• Spironolactone: Increase in 25-50 mg increments up to 400 mg/day maximum 2
• Eplerenone: Increase in 25-100 mg increments up to 200-300 mg/day in divided doses 2

Dose Adjustment Algorithm for Heart Failure:

• Start at 25 mg once daily for both agents
• Target dose: spironolactone 50 mg once daily or eplerenone 50 mg once daily 3, 4
• Titrate after 4-8 weeks if tolerated 3, 4

Monitoring Schedule

Check serum potassium and renal function at 1 week and 4 weeks after initiation or dose change, then at 1,2,3, and 6 months after achieving maintenance dose, then every 6 months thereafter. 3, 4, 5

For primary aldosteronism specifically, monitor electrolytes, renal function, and renin within 2-3 months of starting therapy. 1 More frequent monitoring is needed in patients with:

• Prior severe hypokalemia
• Renal impairment
• Concurrent ACE inhibitor/ARB use
• Elderly patients

Managing Adverse Effects

Hyperkalemia Management:

• K+ 5.5-5.9 mEq/L: Halve the dose (e.g., 25 mg every other day) and monitor closely 3, 4
• K+ ≥6.0 mEq/L: Stop MRA immediately, monitor closely, and provide specific hyperkalemia treatment 3, 4
• Restart at 25 mg every other day when K+ falls to <5.5 mEq/L 6

Worsening Renal Function:

• Creatinine >220 μmol/L (2.5 mg/dL): Halve the dose 3, 4
• Creatinine >310 μmol/L (3.5 mg/dL): Stop MRA immediately 3, 4
• Note: Initial GFR decrease over days-to-weeks often represents treatment efficacy rather than adverse effect, typically stabilizing long-term 1
• If progressive decline occurs, refer to nephrology and discontinue ACE inhibitors/ARBs 1

Gynecomastia:

• Occurs in 10% of men on spironolactone 25 mg/day (up to 52% at ≥150 mg/day) 2
• May appear 1-2 months into therapy but more commonly after ≥6 months 1
• Switch to eplerenone if breast tenderness/enlargement develops 3, 4, 3
• Dose reduction to ≤50 mg/day may resolve gynecomastia in younger males 1

When to Prefer Eplerenone Over Spironolactone

Eplerenone is preferred in men to avoid anti-androgenic side effects (gynecomastia, decreased libido), though it requires 2-3 times higher doses than spironolactone for equivalent efficacy. 2 Eplerenone lacks the anti-androgenic effects due to greater mineralocorticoid receptor selectivity. 2, 7

Specific Indications for Eplerenone:

• Men with breast discomfort/enlargement on spironolactone 3, 4, 3
• Post-MI heart failure (specific FDA indication) 4, 6
• Patients who cannot tolerate spironolactone's hormonal side effects

Important Caveats:

• Eplerenone is metabolized by CYP3A4, requiring dose adjustment with moderate CYP3A inhibitors (max 25 mg once daily in heart failure, 25 mg twice daily in hypertension) 6
• Contraindicated with strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) 6
• Real-world data shows no difference in cardiovascular outcomes between eplerenone and spironolactone in heart failure, but spironolactone is withdrawn more frequently (53% vs 34%) 8
• In primary aldosteronism, spironolactone demonstrated superior blood pressure reduction compared to eplerenone in head-to-head trials 9

Contraindications

Absolute Contraindications (Both Agents):

• Serum potassium >5.5 mEq/L at initiation 6
• eGFR ≤30 mL/min/1.73 m² 6
• Strong CYP3A inhibitors 6

Additional Contraindications for Hypertension Treatment:

• Type 2 diabetes with microalbuminuria (eplerenone) 6
• Creatinine >2.0 mg/dL (men) or >1.8 mg/dL (women) 6
• Concurrent potassium supplements or potassium-sparing diuretics 6

Special Populations:

• Pregnancy: Use alpha-methyldopa instead due to risk of fetal feminization with spironolactone 2
• Stage 3 CKD: Use with extreme caution due to hyperkalemia risk 2
• Elderly/frail patients: Start at lower doses (12.5 mg spironolactone) with careful monitoring 2, 1